Formycon AG and Fresenius Kabi have announced the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar, in Canada. This product is available in both subcutaneous and intravenous ...

Swissnet Group has announced its preliminary unaudited financial results for FY2024, showcasing significant growth aligned with previous guidance. The company's revenue reached CHF 13.1 million, ...

At the Annual General Meeting on May 23, 2025, Ernst Russ AG saw significant management changes and shareholder approvals in Hamburg. All agenda points were resolved with strong support for management ...